Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 3Phase 1 3Phase 3 2Phase 2/3 1

Status

Recruiting 2Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma 14Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 8Lymphoma, Mantle-Cell 7Burkitt Lymphoma 7Rhabdomyosarcoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 5Leukemia 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sarcoma, Ewing 3Lymphoma, Primary Effusion 3Sarcoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Osteosarcoma 2Neuroblastoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Temozolomide 6Irinotecan 6Vincristine 3PM 01183 3Nivolumab 3X-Rays 2Cyclophosphamide 2temsirolimus 1talazoparib 1surufatinib 1silmitasertib 1seclidemstat 1rubitecan 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1irinotecan sucrosofate 1eribulin 1entrectinib 1efineptakin alfa 1dinutuximab 1copanlisib 1bempegaldesleukin 1anlotinib 1alovudine 1abemaciclib 1Zoledronic Acid 1Trabectedin 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Ewing × Vincristine × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04890093 2026-03-16

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
64 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡